Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00017459 · ClinicalTrials.gov registry record · Phase 3

Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

A Phase 3 study, sponsored by Sanofi.

Completed
Registry status
Phase 3
Development phase

NCT00017459 is a Phase 3 study that has completed, run by Sanofi.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00017459, a Phase 3 study, has completed, sponsored by Sanofi.

COMPLETED
Registry status
Phase 3
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if cisplatin and vinorelbine are more effective with or without tirapazamine in treating non-small cell lung cancer PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin plus vinorelbine with or without tirapazamine in treating patients who have stage IIIB or stage IV non-small cell lung cancer.

Interventions

  • DRUG cisplatin
  • DRUG vinorelbine tartrate
  • DRUG tirapazamine

Trial Details

FieldValue
Start Date 2000-07
Est. Completion 2004-02
Phase Phase 3

Sponsor

Sanofi

713 total trials

What the Registry Record Tells You About NCT00017459

The ClinicalTrials.gov registry entry for NCT00017459 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.

NCT00017459 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00017459 about?

NCT00017459 is a clinical study titled "Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if cisplatin and vinorelbine are more effective with or without tirapazamine in treating non-small cell lung cancer PURPOSE: Randomized phase III trial to comp...

What is the current status of trial NCT00017459?

This trial is currently completed. It is a Phase 3 study. The study started on 2000-07. Estimated completion is 2004-02.

What interventions are being tested in trial NCT00017459?

The interventions under investigation include: cisplatin (DRUG), vinorelbine tartrate (DRUG), tirapazamine (DRUG).

Who is sponsoring clinical trial NCT00017459?

This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.